Canada approves SyntheMed's adhesion film
This article was originally published in Clinica
REPEL-CV, SyntheMed's bioresorbable adhesion barrier film, has been approved in Canada for use in paediatric patients who undergo open heart surgery. The film is designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions – scar tissue that can cause the heart to attach to the sternum and other surrounding tissue surfaces. Hasselt, Belgium-based SyntheMed says it is intended to provide the therapeutic benefit and then degrade so that it is cleared from the body. REPEL-CV will be marketed throughout Canada by Force3 Medicale, a Montreal-based distributor of cardiac surgery products. It was CE marked for sale in Europe for use in all heart surgery patients in August 2006 (see Clinica No 1221, p 16). US FDA approval for use in paediatric patients is pending.